Key Takeaways Tempus AI delivered its first positive adjusted EBITDA as revenue jumped 84.7% to $334.2 million.Genomics revenue more than doubled, led by oncology and hereditary testing with 217,000 clinical tests run.TEM sees 2025 revenue of $1.265B and expects $20M adjusted EBITDA in Q4 on pricing and scale benefits.Tempus AI (TEM) reported non-GAAP profit in the third quarter of 2025 as genomics testing and data services gained momentum. The stock carries a Zacks Rank #3 (Hold) with a VGM Score of D. It ...